Omeros (OMER) 10-Q7 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 06, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'OMER	'
Entity Registrant Name	'OMEROS CORP	'
Entity Central Index Key	'0001285819	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	30,319,951

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$1,150	$1,520
Short-term investments	7,848	20,830
Grant and other receivables	881	1,934
Prepaid expenses and other current assets	391	416
Total current assets	10,270	24,700
Property and equipment, net	952	1,037
Restricted cash	679	679
Other assets	113	159
Total assets	12,014	26,575
Current liabilities:	'	'
Accounts payable	3,361	2,632
Accrued expenses	4,520	4,757
Deferred revenue	0	970
Current portion of notes payable, net of discount	4,019	0
Total current liabilities	11,900	8,359
Notes payable, net of current portion and discount	16,376	20,103
Deferred rent	7,631	4,644
Commitments and contingencies (Note 8)	'	'
Shareholdersâ€™ equity:	'	'
Preferred stock, par value $0.01 per share: Authorized shares - 20,000,000 at September 30, 2013 (unaudited) and December 31, 2012; Issued and outstanding sharesâ€”none	'	'
Common stock, par value $0.01 per share: Authorized shares - 150,000,000 at September 30, 2013 (unaudited) and December 31, 2012; Issued and outstanding sharesâ€”29,849,830 and 25,897,483 at September 30, 2013 (unaudited) and December 31, 2012, respectively	298	259
Additional paid-in capital	228,337	207,787
Accumulated deficit	-252,528	-214,577
Total shareholdersâ€™ deficit	-23,893	-6,531
Total liabilities and shareholdersâ€™ equity	$12,014	$26,575

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, par value (USD per share)	$0.01	$0.01
Preferred stock, authorized shares	20,000,000	20,000,000
Preferred stock, Issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value (USD per share)	$0.01	$0.01
Common stock, authorized shares	150,000,000	150,000,000
Common stock, Issued shares	29,849,830	25,897,483
Common stock, outstanding shares	29,849,830	25,897,483

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue	$196	$1,417	$1,431	$4,439
Operating expenses:	'	'	'	'
Research and development	9,420	7,764	26,111	22,568
Selling, general and administrative	4,210	2,736	11,934	7,270
Litigation settlement	0	3,953	0	3,953
Total operating expenses	13,630	14,453	38,045	33,791
Loss from operations	-13,434	-13,036	-36,614	-29,352
Investment income	2	14	10	32
Interest expense	-592	-413	-1,768	-1,360
Other income (expense), net	154	159	421	-30
Net loss	-13,870	-13,276	-37,951	-30,710
Comprehensive loss	($13,870)	($13,276)	($37,951)	($30,710)
Basic and diluted net loss per share (USD per share)	($0.46)	($0.51)	($1.36)	($1.30)
Weighted-average shares used to compute basic and diluted net loss per share (shares)	29,844,507	25,834,730	27,984,133	23,578,724

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating activities	'	'
Net loss	($37,951)	($30,710)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	222	232
Stock-based compensation expense	4,364	2,276
Non-cash interest expense	371	290
Warrant modification expense	41	511
Changes in operating assets and liabilities:	'	'
Grant and other receivables	1,053	408
Prepaid expenses and other current and noncurrent assets	31	-242
Accounts payable and accrued expenses	453	1,702
Accrued settlement costs	0	3,953
Deferred revenue	-970	-3,278
Other liabilities	2,987	3,091
Net cash used in operating activities	-29,399	-21,767
Investing activities	'	'
Purchases of property and equipment	-137	-235
Purchases of investments	-22,963	-38,819
Proceeds from the sale of investments	35,945	29,815
Net cash provided by (used in) investing activities	12,845	-9,239
Financing activities	'	'
Proceeds from issuance of common stock	16,120	32,306
Payments on notes payable	0	-4,596
Proceeds from issuance of common stock upon exercise of stock options	64	351
Net cash provided by financing activities	16,184	28,061
Net (decrease) in cash and cash equivalents	-370	-2,945
Cash and cash equivalents at beginning of period	1,520	4,005
Cash and cash equivalents at end of period	1,150	1,060
Supplemental cash flow information	'	'
Cash paid for interest	1,243	1,103
Reduction of equipment cost basis due to assets purchased with grant funding	$0	$59

Organization_and_Significant_A

Organization and Significant Accounting Policies	9 Months Ended
Organization and Significant Accounting Policies	Sep. 30, 2013
Organization and Significant Accounting Policies	'
	Organization and Significant Accounting Policies
	Organization
	We are a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Our most clinically advanced product, OMS302 for lens replacement surgery, is derived from our proprietary PharmacoSurgery® platform that is designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our efforts are devoted to conducting research and development of our products, developing our patent portfolio, raising capital and commercializing our products.
	Cash Generation Subsequent to September 30, 2013
	In October, 2013, we settled our outstanding lawsuit with Carolina Casualty Insurance Corporation, or CCIC, and received a $12.5 million payment on October 24, 2013 (see Note 8). In addition, during October 2013, we sold 373,700 shares of our common stock through our at-the-market equity facility at an average price of $13.29 per share and received net proceeds of $4.9 million (see Note 9). We continue to seek additional means of accessing cash through a variety of sources including licensing of one or more of our programs, grants, and debt financings, as well as equity transactions.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of September 30, 2013 and for the three and nine months ended September 30, 2013 and 2012, includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. As of December 31, 2012, deferred rent totaling $959,000 was reclassified from current liabilities to non-current liabilities in the accompanying balance sheet as management does not have the obligation or intention to pay this rent prior to December 31, 2013.
	The accompanying unaudited consolidated financial statements and notes to consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included in our Annual Report on Form 10-K for the year ended December 31, 2012.
	Segments
	We operate in one segment. Management uses cash flow as the primary measure to manage our business and does not segment our business for internal reporting or decision-making.
	Principles of Consolidation
	Our consolidated financial statements include the financial position and results of operations of Omeros Corporation, or Omeros, and nura, inc., or nura, our wholly owned subsidiary.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from those estimates.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2013
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of unrestricted common shares and dilutive common share equivalents outstanding for the period, determined using the treasury-stock method. The basic and diluted net loss per share amounts for the three and nine months ended September 30, 2013 and 2012 were computed based on the shares of common stock outstanding during the respective periods. Historical outstanding dilutive securities not included in the diluted loss per share calculation are as follows:



		September 30,
		2013	2012
	Outstanding options to purchase common stock	6,909,332	4,120,225

	Warrants to purchase common stock	609,016	609,016

	Total	7,518,348	4,729,241

Cash_Cash_Equivalents_and_Inve

Cash, Cash Equivalents and Investments	9 Months Ended
Cash, Cash Equivalents and Investments	Sep. 30, 2013
Cash, Cash Equivalents and Investments	'
	Cash, Cash Equivalents and Investments
	As of September 30, 2013 and December 31, 2012, all investments are classified as short-term and available-for-sale on the accompanying consolidated balance sheets. We did not own any securities with unrealized loss positions as of September 30, 2013 or December 31, 2012. Investment income consists primarily of interest income.

FairValue_Measurements

Fair-Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair-Value Measurements	'
	Fair-Value Measurements
	On a recurring basis, we measure certain financial assets at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:
	Level 1—Observable inputs for identical assets or liabilities, such as quoted prices in active markets;
	Level 2—Inputs other than quoted prices in active markets that are either directly or indirectly observable; and
	Level 3—Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.
	Our fair-value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:



		30-Sep-13
		Level 1		Level 2		Level 3		Total
		(In thousands)
	Assets:
	Money-market funds classified as cash equivalents	$	19	$	—	$	—	$	19

	Money-market funds classified as current restricted cash	193		—		—		193

	Money-market funds classified as non-current restricted cash	679		—		—		679

	Money-market funds classified as short-term investments	7,848		—		—		7,848

	Total	$	8,739	$	—	$	—	$	8,739




		31-Dec-12
		Level 1		Level 2		Level 3		Total
		(In thousands)
	Assets:
	Money-market funds classified as cash equivalents	$	21	$	—	$	—	$	21

	Money-market funds classified as current restricted cash	193		—		—		193

	Money-market funds classified as non-current restricted cash	679		—		—		679

	Money-market funds classified as short-term investments	20,830		—		—		20,830

	Total	$	21,723	$	—	$	—	$	21,723

	Money-market funds classified as current restricted cash are included in prepaid expenses and other current assets on the accompanying consolidated balance sheets. Cash of $1.1 million and $1.5 million is excluded from our fair-value hierarchy disclosure as of September 30, 2013 and December 31, 2012, respectively. There were no unrealized gains and losses associated with our short-term investments as of September 30, 2013 or December 31, 2012.

Certain_Balance_Sheet_Accounts

Certain Balance Sheet Accounts	9 Months Ended
	Sep. 30, 2013
Certain Balance Sheet Accounts	'
	Certain Balance Sheet Accounts
	Accrued Expenses
	Accrued expenses consisted of the following:



		September 30,		December 31,
		2013		2012
		(In thousands)
	National Institute of Health reimbursement (see Note 8)	$	1,064	$	—

	Legal	740		323

	Clinical trials	697		1,842

	Contract research	594		1,447

	Employee compensation	588		458

	Consulting & professional fees	467		252

	Other accruals	370		435

	Total	$	4,520	$	4,757

Notes_Payable

Notes Payable	9 Months Ended
Notes Payable	Sep. 30, 2013
Notes Payable	'
	Notes Payable
	In October 2010, we entered into a loan and security agreement with Oxford Finance LLC, or Oxford. We refer to this loan agreement, as amended, as the Loan Agreement. Under the Loan Agreement, we had $20.0 million in principal outstanding indebtedness as of September 30, 2013 and December 31, 2012. In connection with the Loan Agreement, we agreed to pay Oxford a final payment fee of $1.4 million, which we recorded as a discount on the outstanding debt. Interest accrues at a fixed annual rate of 9.25%. The Loan Agreement provides for interest-only payments through December 31, 2013. Beginning on January 1, 2014, payments of principal and interest are payable for 36 months, in arrears. All unpaid principal, the final exit fee, and accrued and unpaid interest are due and payable on the maturity date, December 1, 2016. As security for our obligations under the Loan Agreement, we granted Oxford a security interest in substantially all of our assets, excluding intellectual property. As of September 30, 2013, the remaining unamortized discount and debt issuance costs associated with the debt were $1.1 million and $128,000, respectively.

Revenue

Revenue	9 Months Ended
Revenue	Sep. 30, 2013
Revenue	'
	Revenue
	We have received Small Business Innovative Research grants from the National Institutes of Health, or NIH, which are used to support the research and development of our products. We recorded revenue related to these grants of $196,000 and $88,000 for the three months ended September 30, 2013 and 2012, respectively, and $461,000 and $577,000 for the nine months ended September 30, 2013 and 2012, respectively. As of September 30, 2013, $1.4 million remained available under these grants.
	In October 2010, we entered into a platform development funding agreement with Vulcan Inc. and its affiliate, which we refer to collectively as Vulcan, pursuant to which we received $20.0 million for our G protein-coupled receptor, or GPCR, program. Of the funds received from Vulcan, $10.8 million was recorded as a reduction of the cost of the intellectual property assets that we purchased from Patobios Limited, or Patobios, $994,000 was recorded in equity for the fair value of warrants issued to Vulcan, and the remaining $8.2 million was recorded as deferred revenue. The deferred revenue balance was recognized as revenue or as a reduction to the costs of assets purchased in direct proportion to the related GPCR expenses as they were incurred. We recognized as revenue the remaining deferred revenue balance of $970,000 under the Vulcan agreement during the first quarter of 2013 and therefore, no additional revenue was recognized during the three months ended September 30, 2013. For the three months ended September 30, 2012, we recorded reductions to the Vulcan deferred revenue balance of $1.3 million, which includes $1.3 million recognized as revenue and $0 recorded as cost reductions to assets. For the nine months ended September 30, 2013 and 2012, we recorded reductions of $970,000 and $3.2 million to the Vulcan deferred revenue balance, respectively. For the nine months ended September 30, 2012, the reduction included $3.2 million recorded as revenue and $60,000 recorded as cost reductions to assets. Also in October 2010, we entered into an agreement with the Life Sciences Discovery Fund Authority, a granting agency of the State of Washington, or LSDF, under which we received a $5.0 million grant award from LSDF that was paid to reimburse us for expenses we incurred and equipment we purchased related to our GPCR program. We recognized the remaining $624,000 of revenue under the LSDF agreement during the first quarter of 2012.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2013
Commitments and Contingencies	'
	Commitments and Contingencies
	Litigation
	Omeros and its chief executive officer, Gregory A. Demopulos, M.D., entered into a Settlement Agreement with Richard J. Klein, Omeros' former chief financial officer, in October 2012, to resolve a lawsuit filed by Mr. Klein alleging wrongful termination of Mr. Klein’s employment and asserting qui tam claims on behalf of the U.S. Government under the Federal False Claims Act related to two National Institute of Health, or NIH, grants. Pursuant to the terms of the Settlement Agreement, Omeros paid $3.95 million to Mr. Klein, which was recorded as litigation settlement expense in the quarter ended September 30, 2012, and all claims pending in the lawsuit were dismissed with prejudice to the parties in November 2012. The dismissal of these claims was without prejudice to the U.S. Government, which previously had declined to intervene in the lawsuit. The $3.95 million settlement cost was reimbursed to Omeros by its insurer, CCIC, during the quarter ended December 31, 2012.
	In connection with an administrative review by NIH of the grants that were the subject of the Klein lawsuit, Omeros recognized $900,000 in the first quarter of 2013 and $164,000 in the third quarter of 2013 as selling, general and administrative expense. In October 2013, Omeros paid NIH the $1.064 million previously accrued. The administrative review will be complete following a review of Omeros’ financial systems related to the allocation of expenditures to cost categories for use by Omeros in current and any future grants.
	On October 2, 2013, Omeros and its chief executive officer entered into a settlement agreement with CCIC related to CCIC’s defense of, and coverage obligations related to, the Klein lawsuit. Per the settlement agreement, CCIC paid Omeros $12.5 million on October 24, 2013. While Dr. Demopulos released all of his claims in exchange for this settlement, he elected to receive no portion of the settlement funds and to have all proceeds be paid to Omeros.
	Contracts
	In December 2006, we entered into a funding agreement with The Stanley Medical Research Institute, or SMRI, to develop a proprietary phosphodiesterase 10, or PDE10, inhibitor product for the treatment of schizophrenia. We hold the exclusive rights to the technology. In connection with the funding agreement with SMRI, beginning the first calendar year after commercial sales of a schizophrenia product, if and when a product is commercialized, we may become obligated to pay royalties based on net income, as defined in the agreement, not to exceed a set multiple of total grant funding received. Based on the amount of grant funding received as of September 30, 2013, the maximum amount of royalties payable by us under the agreement is $12.8 million. We have not paid any such royalties through September 30, 2013.
	In February 2009, we entered into a patent assignment agreement with an individual whereby we acquired all intellectual property rights, including patent applications, related to peroxisome proliferators activated receptor gamma, or PPARγ, agonists for the treatment and prevention of addictions to substances of abuse, as well as other compulsive behaviors. No payments were made related to the technology acquisition. In February 2011, we amended the patent assignment agreement to include all intellectual property rights, including patent applications, related to dietary supplements that increase PPARγ activity. Under the agreement, we will be required to make payments to the individual of up to $3.8 million in total, for both PPARγ agonists and dietary supplements that increase PPARγ activity, upon achievement of certain development events, such as the initiation of clinical trials and receipt of marketing approval. In addition, we are obligated to pay a low single-digit percentage royalty on any net sales of drug products that are covered by any patents that issue from the acquired patent application.
	In March 2010, we entered into a license agreement with Daiichi Sankyo Co., Ltd. (successor-in-interest to Asubio Pharma Co., Ltd.), or Daiichi Sankyo, pursuant to which we received an exclusive license to phosphodiesterase 7, or PDE7, inhibitors claimed in certain patents and pending patent applications owned by Daiichi Sankyo for use in the treatment of movement disorders and other specified indications. In February 2011, we amended the agreement to include addiction and compulsive disorders in the field of use. In January 2013, we further amended the agreement to include all other indications except specified dermatologic conditions. Upon execution of the agreement, we paid Daiichi Sankyo $50,000 that was recognized as research and development expense. Under the amended agreement, we agreed to make milestone payments to Daiichi Sankyo of up to $33.5 million upon the achievement of certain events, such as successful completion of certain preclinical toxicology studies; dosing of human subjects in Phase 1, 2 and 3 clinical trials; receipt of marketing approval of a PDE7 inhibitor product; and reaching specified sales milestones. However, if only one of the three indications is advanced through each milestone, the total milestone payments would be $23.5 million. In addition, Daiichi Sankyo is entitled to receive from us a low single-digit percentage royalty of any net sales of a PDE7 inhibitor licensed under the agreement by us and/or our sublicensee(s), provided that if the sales are made by a sublicensee, then the amount payable by us to Daiichi Sankyo is capped at an amount equal to a low double-digit percentage of all royalty and specified milestone payments that we receive from the sublicensee.
	In April 2010, we entered into an exclusive license agreement with Helion Biotech ApS, or Helion, pursuant to which we received a royalty bearing, worldwide exclusive license in and to all of Helion’s intellectual property rights related to mannan-binding lectin-associated serine protease-2, or MASP-2, antibodies, polypeptides and methods in the field of inhibition of mannan-binding lectin-mediated activation of the complement system for the prevention, treatment or diagnosis of any disease or condition. Upon execution of the agreement, we paid Helion $500,000 that was recognized as research and development expense and agreed to make development and sales milestone payments to Helion of up to an additional $6.9 million upon the achievement of certain events, such as the filing of an Investigational New Drug Application, or IND, with the U.S. Food and Drug Administration, or FDA; initiation of Phase 2 and 3 clinical trials; receipt of marketing approval; and reaching specified sales milestones. In addition, Helion is entitled to receive from us a low single-digit percentage royalty of any net sales of a MASP-2 inhibitor product that is covered by the patents licensed by us under the agreement.
	In connection with our funding agreements with Vulcan and LSDF discussed in Note 7, we have agreed to pay Vulcan and LSDF tiered percentages of the net proceeds, if any, derived from the GPCR program. The percentage rates of net proceeds payable to Vulcan and LSDF decrease as the cumulative net proceeds reach specified thresholds, and the blended percentage rate payable to Vulcan and LSDF in the aggregate is in the mid-teens with respect to the first approximately $1.5 billion of cumulative net proceeds that we receive from our GPCR program. If we receive cumulative net proceeds in excess of approximately $1.5 billion, the percentage rate payable to Vulcan and LSDF in the aggregate decreases to one percent. Pursuant to the agreement with Vulcan, at our option, we may pay a portion of Vulcan’s share of the one percent of net proceeds to a life sciences initiative, or LSI, to be established in accordance with the LSDF agreement. The LSI will be a non-profit, tax-exempt organization with a mission to advance life sciences in the State of Washington.
	Net proceeds are defined in the Vulcan and LSDF agreements as (1) all consideration received by us in any form relating directly to the GPCR program, such as from license fees, milestone fees, royalties, product sales, partnerships and a transfer of the GPCR program to a third party, subject to exceptions specified in such agreements, less (2) all expenses and expenditures in excess of $25.0 million incurred by us in connection with the GPCR program such as for research and development, related overhead, milestone and royalty payments, legal expenses, cost of goods sold and product sales deductions. Any consideration that we receive (a) from government entities (subject to specified exceptions), (b) from third parties that have designated such consideration for the purpose of funding research and development expenses and related overhead or (c) in the form of grants, as well as any expenses or expenditures that we incur that are paid for with such consideration, are excluded for purposes of determining net proceeds.
	In November 2010, pursuant to our agreement with Vulcan, we purchased from Patobios intellectual property assets related to an assay technology for use in the GPCR program. We also issued to Vulcan three warrants to purchase our common stock, each with a five-year term and exercisable for 133,333 shares, with exercise prices of $20, $30 and $40 per share, respectively. The exercise price of the warrants may be paid in cash or on a “cashless” basis in which the number of shares issuable upon exercise of the warrant would be reduced by the number of shares having a fair market value equal to the applicable exercise price. Under our agreement with Vulcan, we granted Vulcan a security interest in our personal property related to the GPCR program, other than intellectual property, which security interest is junior to any existing or future security interests granted in connection with a financing transaction and which will be released automatically after Vulcan receives $25.0 million under the agreement. We also agreed not to grant any liens on intellectual property related to the GPCR program. The term of our agreement with Vulcan is 35 years, provided that the term will automatically extend until the cumulative net proceeds that we receive from the GPCR program are approximately $1.5 billion.
	Under our agreement with LSDF, after LSDF receives $25.0 million from us, any remaining amounts that would be payable by us to LSDF pursuant to the agreement will instead be paid to LSI. Our obligations with respect to LSI are limited to creating LSI’s charter documents, incorporating LSI, selecting directors and applying for tax-exempt status, all in consultation with LSDF. We have no other obligations, funding or otherwise, to LSI. The term of our agreement with LSDF expires on the six-month anniversary following the last date that we deliver a report related to our incurrence of grant-funded expenses described in the agreement, provided that certain obligations will survive the expiration of the term. The term of our payment obligations to LSDF is the same as that under our agreement with Vulcan.
	We currently lease our office and laboratory in The Omeros Building under a lease agreement with BMR-201 Elliott Avenue LLC, or BMR. The initial term of the lease ends in November 2027 and we have two options to extend the lease term, each by five years. As of September 30, 2013, the remaining aggregate non-cancelable rent payable under the initial term of the lease is approximately $61.7 million and we have received net lease incentives of $4.5 million, which are recorded as deferred rent on our accompanying consolidated balance sheets. The additional $3.1 million of the deferred rent balance as of September 30, 2013 relates to rent deferrals since inception of our lease in November 2012.

Shareholders_Equity

Shareholders' Equity	9 Months Ended
Shareholders' Equity	Sep. 30, 2013
Shareholders' Equity	'
	Shareholders’ Equity
	MLV At-the-Market Agreement
	In December 2012, we entered into an at-the-market issuance sales agreement with MLV, or the Sales Agreement. Pursuant to the Sales Agreement, we may direct MLV to sell shares of our common stock having an aggregate offering price of up to $44.4 million directly on The NASDAQ Global Market or through or to a market maker other than on an exchange. With our prior written consent, sales may also be made in negotiated transactions and/or any other method permitted by law. MLV will receive a 2% commission from the gross proceeds of any sales. Subject to the terms and conditions of the Sales Agreement, MLV will use its commercially reasonable efforts to sell the shares of our common stock from time to time, based upon our instructions (including any price, time or size limits or other parameters or conditions that we may impose). We are not obligated to make any sales of common stock under the Sales Agreement, and no assurance can be given that we will sell any additional shares under the Sales Agreement, or, if we do, as to the price or amount of shares that we will sell, or the dates on which any such sales will take place. The Sales Agreement may be terminated by either party at any time upon 10 days’ notice to the other party, or by MLV at any time in certain circumstances, including the occurrence of a material adverse effect to Omeros. In addition, the Sales Agreement will automatically terminate upon the sale of all common stock subject to the Sales Agreement, or upon the expiration of our currently effective shelf registration statement. Our currently effective shelf registration statement will expire upon the earlier of (1) the effective date of the replacement shelf registration statement that we filed with the U.S. Securities and Exchange Commission, or SEC, on October 17, 2013 and (2) April 16, 2014. We are in discussions to amend the Sales Agreement to continue under the replacement shelf registration statement, if and when declared effective. In October 2013, we sold 373,700 shares of our common stock at an average price of $13.29 per share under the Sales Agreement and received net proceeds of $4.9 million.
	Direct Offering
	In May 2013, we sold 3,903,004 shares of our common stock at a price of $4.14 per share in a registered direct offering. After deducting offering expenses of $39,000, we received net proceeds from the transaction of $16.1 million.
	Warrants
	On March 29, 2007, we issued five-year warrants to purchase up to an aggregate of 197,478 shares of our common stock at an exercise price of $12.25 per share to brokers who assisted us in connection with our Series E Preferred Stock financing. On March 28, 2012, we extended by one year the expiration dates of those warrants. As a result of the extension, the expiration date of these warrants was March 29, 2013. On March 28, 2013, we extended the expiration dates of the warrants an additional year to March 29, 2014. Pursuant to accounting guidance regarding equity-based compensation to non-employees, we evaluated the value of the warrants before and after the modification dates to determine the incremental change in their fair value. For the nine months ended September 30, 2013 and 2012, we recorded these changes in fair value of $41,000 and $511,000, respectively, in other expense.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation	'
	Stock-Based Compensation
	Stock Options
	Our 2008 Equity Incentive Plan, or 2008 Plan, provides for the grant of incentive and nonstatutory stock options, restricted stock, stock appreciation rights, performance units and performance shares to employees, directors and consultants and subsidiary corporations’ employees and consultants. The 2008 Plan also allows any shares returned under our Amended and Restated 1998 Stock Option Plan, or 1998 Plan, as a result of cancellation of options or repurchase of shares issued pursuant to the 1998 Plan, to be issued under the 2008 Plan. In addition, the 2008 Plan provides for annual increases in the number of shares available for issuance thereunder on the first day of each fiscal year, beginning with the 2010 fiscal year, equal to the lowest of:

	•	five percent of the outstanding shares of our common stock on the last day of the immediately preceding fiscal year;

	•	1,785,714 shares; or

	•	such other amount as our board of directors may determine.
	On January 1, 2013, in accordance with the 2008 Plan annual increase provisions, the authorized shares in the 2008 Plan increased by 1,294,874 shares. As of September 30, 2013, a total of 7,520,691 shares were reserved for issuance under our stock plans, of which 611,359 were available for future grants under the 2008 Plan. Options are granted with exercise prices equal to the closing fair market value of the common stock on the date of the grant. The terms of options may not exceed 10 years. Generally, options vest over a four-year period, but may be granted with different vesting terms.
	Compensation cost for stock options granted to employees is based on the grant-date fair value and is recognized over the vesting period of the applicable option on a straight-line basis. As stock-based compensation expense is based on options ultimately expected to vest, the expense has been reduced for estimated forfeitures. The fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option- pricing model with the following assumptions during the periods ended:



		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2013				2012				2013			2012
	Estimated weighted-average fair value	$	6.77			$	6.63			$	6.73		$	3.32

	Weighted-average assumptions
	Expected volatility	88		%		84		%		87		%	89		%
	Expected term, in years	5.8				6				5.8			5.7

	Risk-free interest rate	1.66		%		0.83		%		1.65		%	1.05		%
	Expected dividend yield	—		%		—		%		—		%	—		%
	Stock-Based Compensation Summary
	Stock-based compensation expense includes amortization of stock options granted to employees and non-employees’ and has been reported in our consolidated statements of operations as follows:



		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2013				2012				2013			2012
		(In thousands)								(In thousands)
	Research and development	$	1,371			$	282			$	2,518		$	1,135

	Selling, general and administrative	840				294				1,846			1,141

	Total	$	2,211			$	576			$	4,364		$	2,276

	Stock option activity for all stock plans and related information is as follows:



		Options			Weighted-				Remaining		Aggregate
		Outstanding			Average				Contractual Life		Intrinsic
					Exercise				(in years)		Value
					Price per						(In thousands)
					Share
	Balance at December 31, 2012	5,390,582			$	5.18

	Granted	1,734,301			9.31

	Exercised	(49,343	)		1.29

	Forfeited	(166,208	)		7.42

	Balance at September 30, 2013	6,909,332			$	6.19			7.34		$	25,351

	Vested and expected to vest at September 30, 2013	6,605,953			$	6.08			7.25		$	24,973

	Exercisable at September 30, 2013	3,873,323			$	4.26			5.82		$	21,525

At September 30, 2013, there were 3,036,009 unvested options outstanding that will vest over a weighted-average period of 2.9 years. Excluding non-employee stock options, the total estimated compensation expense to be recognized in connection with these shares is $16.0 million.

Organization_and_Significant_A1

Organization and Significant Accounting Policies (Policies)	9 Months Ended
Organization and Significant Accounting Policies (Policies)	Sep. 30, 2013
Organization	'
	Organization
	We are a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Our most clinically advanced product, OMS302 for lens replacement surgery, is derived from our proprietary PharmacoSurgery® platform that is designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our efforts are devoted to conducting research and development of our products, developing our patent portfolio, raising capital and commercializing our products.
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The information as of September 30, 2013 and for the three and nine months ended September 30, 2013 and 2012, includes all adjustments, which include normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. As of December 31, 2012, deferred rent totaling $959,000 was reclassified from current liabilities to non-current liabilities in the accompanying balance sheet as management does not have the obligation or intention to pay this rent prior to December 31, 2013.
	The accompanying unaudited consolidated financial statements and notes to consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto that are included in our Annual Report on Form 10-K for the year ended December 31, 2012.
Segments	'
	Segments
	We operate in one segment. Management uses cash flow as the primary measure to manage our business and does not segment our business for internal reporting or decision-making.
Principles of Consolidation	'
	Principles of Consolidation
	Our consolidated financial statements include the financial position and results of operations of Omeros Corporation, or Omeros, and nura, inc., or nura, our wholly owned subsidiary.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from those estimates.

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss per Share	'
	Historical outstanding dilutive securities not included in the diluted loss per share calculation are as follows:



		September 30,
		2013	2012
	Outstanding options to purchase common stock	6,909,332	4,120,225

	Warrants to purchase common stock	609,016	609,016

	Total	7,518,348	4,729,241

FairValue_Measurements_Tables

Fair-Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	Our fair-value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis are as follows:



		30-Sep-13
		Level 1		Level 2		Level 3		Total
		(In thousands)
	Assets:
	Money-market funds classified as cash equivalents	$	19	$	—	$	—	$	19

	Money-market funds classified as current restricted cash	193		—		—		193

	Money-market funds classified as non-current restricted cash	679		—		—		679

	Money-market funds classified as short-term investments	7,848		—		—		7,848

	Total	$	8,739	$	—	$	—	$	8,739




		31-Dec-12
		Level 1		Level 2		Level 3		Total
		(In thousands)
	Assets:
	Money-market funds classified as cash equivalents	$	21	$	—	$	—	$	21

	Money-market funds classified as current restricted cash	193		—		—		193

	Money-market funds classified as non-current restricted cash	679		—		—		679

	Money-market funds classified as short-term investments	20,830		—		—		20,830

	Total	$	21,723	$	—	$	—	$	21,723

Certain_Balance_Sheet_Accounts1

Certain Balance Sheet Accounts (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Expenses	'
	Accrued expenses consisted of the following:



		September 30,		December 31,
		2013		2012
		(In thousands)
	National Institute of Health reimbursement (see Note 8)	$	1,064	$	—

	Legal	740		323

	Clinical trials	697		1,842

	Contract research	594		1,447

	Employee compensation	588		458

	Consulting & professional fees	467		252

	Other accruals	370		435

	Total	$	4,520	$	4,757

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Weighted Average Assumptions for Employee Stock Option Grants	'
	The fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option- pricing model with the following assumptions during the periods ended:



		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2013				2012				2013			2012
	Estimated weighted-average fair value	$	6.77			$	6.63			$	6.73		$	3.32

	Weighted-average assumptions
	Expected volatility	88		%		84		%		87		%	89		%
	Expected term, in years	5.8				6				5.8			5.7

	Risk-free interest rate	1.66		%		0.83		%		1.65		%	1.05		%
	Expected dividend yield	—		%		—		%		—		%	—		%
Stock-Based Compensation Expense	'
	Stock-based compensation expense includes amortization of stock options granted to employees and non-employees’ and has been reported in our consolidated statements of operations as follows:



		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2013				2012				2013			2012
		(In thousands)								(In thousands)
	Research and development	$	1,371			$	282			$	2,518		$	1,135

	Selling, general and administrative	840				294				1,846			1,141

	Total	$	2,211			$	576			$	4,364		$	2,276

Stock Option Activity and Related Information	'
	Stock option activity for all stock plans and related information is as follows:



		Options			Weighted-				Remaining		Aggregate
		Outstanding			Average				Contractual Life		Intrinsic
					Exercise				(in years)		Value
					Price per						(In thousands)
					Share
	Balance at December 31, 2012	5,390,582			$	5.18

	Granted	1,734,301			9.31

	Exercised	(49,343	)		1.29

	Forfeited	(166,208	)		7.42

	Balance at September 30, 2013	6,909,332			$	6.19			7.34		$	25,351

	Vested and expected to vest at September 30, 2013	6,605,953			$	6.08			7.25		$	24,973

	Exercisable at September 30, 2013	3,873,323			$	4.26			5.82		$	21,525

Organization_and_Significant_A2

Organization and Significant Accounting Policies (Detail) (USD $)	3 Months Ended	12 Months Ended	1 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Oct. 31, 2013
	segment	Dec. 31, 2012	Subsequent Event [Member]
Accounting Policies [Abstract]	'	'	'
Reclassification of deferred rent	'	$959,000	'
Number of operating segments	1	'	'
Subsequent Event [Line Items]	'	'	'
Litigation settlement, gross	'	'	12,500,000
Sales Agreement, Number of Shares Sold During Period	'	'	373,700
Sales Agreement, Average Share Price	'	'	$13.29
Sales Agreement, Net Proceeds	'	'	$4,900,000

Net_Loss_Per_Share_Calculation

Net Loss Per Share - Calculation of Historical Outstanding Dilutive Securities Not Included in Diluted Loss Per Share (Detail)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Outstanding dilutive securities not included in diluted loss per share calculation	7,518,348	4,729,241
Outstanding options to purchase common stock	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Outstanding dilutive securities not included in diluted loss per share calculation	6,909,332	4,120,225
Warrants to purchase common stock	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Outstanding dilutive securities not included in diluted loss per share calculation	609,016	609,016

FairValue_Measurements_Financi

Fair-Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Total	$8,739	$21,723
Money Market Funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Money-market funds classified as cash equivalents	19	21
Money-market funds classified as short-term investments	7,848	20,830
Current	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Money-market funds classified as restricted cash	193	193
Non Current	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Money-market funds classified as restricted cash	679	679
Fair Value, Inputs, Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Total	8,739	21,723
Fair Value, Inputs, Level 1 \| Money Market Funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Money-market funds classified as cash equivalents	19	21
Money-market funds classified as short-term investments	7,848	20,830
Fair Value, Inputs, Level 1 \| Current	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Money-market funds classified as restricted cash	193	193
Fair Value, Inputs, Level 1 \| Non Current	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Money-market funds classified as restricted cash	$679	$679

FairValue_Measurements_Narrati

Fair-Value Measurements - Narrative (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash excluded from fair value hierarchy disclosure	$1.10	$1.50

Certain_Balance_Sheet_Accounts2

Certain Balance Sheet Accounts - Accrued Expenses (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]	'	'
National Institute of Health reimbursement (see Note 8)	$1,064	$0
Legal	740	323
Clinical trials	697	1,842
Contract research	594	1,447
Employee compensation	588	458
Consulting & professional fees	467	252
Other accruals	370	435
Total	$4,520	$4,757

Notes_Payable_Detail

Notes Payable (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Loan and security agreement, existing outstanding indebtedness	$20,000,000	$20,000,000
Debt Instrument, Fee Amount	1,400,000	'
Accrued interest rate	9.25%	9.25%
Unamortized balance of debt discount	1,100,000	'
Unamortized balance of debt issuance costs	$128,000	'

Revenue_Detail

Revenue (Detail) (USD $)

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Oct. 31, 2010

Mar. 31, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2012

Oct. 31, 2010

Small Business Innovative Research

Vulcan Incorporated

Life Sciences Discovery Fund Authority

Revenue [Line Items]

Grant revenue recognized

$196,000

$88,000

$461,000

$577,000

$624,000

Remaining available amount under grant

1,400,000

Grants received

20,000,000

Cost reduction to intellectual property assets

10,800,000

Fair value of warrants issued

994,000

Deferred revenue

8,200,000

Maximum contractual amount from grant

5,000,000

Reductions to deferred revenue

970,000

1,300,000

970,000

3,200,000

Deferred Revenue, Revenue Recognized

1,300,000

3,200,000

Reduction of equipment cost basis due to assets purchased with grant funding

$59,000

$60,000

Commitments_and_Contingencies_

Commitments and Contingencies (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

Nov. 30, 2012

Oct. 31, 2012

Nov. 30, 2010

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Mar. 29, 2007

Sep. 30, 2013

Feb. 28, 2011

Jan. 31, 2013

Sep. 30, 2013

Jan. 31, 2013

Apr. 30, 2010

Sep. 30, 2013

Oct. 31, 2010

Oct. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

warrant

Leases

Stanley Medical Research Institute

Individual

Daiichi Sankyo Company Limited

Helion Biotech ApS

Vulcan and Life Sciences Discovery Fund Authority

Vulcan Incorporated

Life Sciences Discovery Fund Authority

Subsequent Event [Member]

Selling, General and Administrative Expenses

Maximum

Scenario 1

Maximum

Warrant 1

Warrant 2

Warrant 3

Commitments and Contingencies Disclosure [Line Items]

Litigation settlement

$3,950,000

Litigation recovery

3,950,000

Prior grants received, under review

164,000

900,000

Loss contingency accrual

1,064,000

Litigation settlement, gross

12,500,000

Potential future payments

12,800,000

3,800,000

23,500,000

33,500,000

6,900,000

Research and development expense

9,420,000

7,764,000

26,111,000

22,568,000

50,000

500,000

Potential future net proceeds

1,500,000,000

Eligible expenses and expenditures deducted for computation of net proceeds

25,000,000

Number of warrants issued

Warrants, exercisable, amount of shares

197,478

133,333

Warrants, term

'5 years

Warrants, exercise price per share

12.25

Amount payable under agreement

25,000,000

Term of agreement

'35 years

Amount payable under agreement

25,000,000

Number of Options to extend the lease term

Options to extend the lease term, number of options

'5 years

Remaining aggregate rent payable

61,700,000

Net lease incentives

4,500,000

Deferred Rent, Less Lease Incentives

$3,100,000

Shareholders_Equity_Detail

Shareholders' Equity (Detail) (USD $)	0 Months Ended			1 Months Ended	9 Months Ended			1 Months Ended
	Mar. 28, 2013	Mar. 28, 2012	Mar. 29, 2007	31-May-13	Sep. 30, 2013	Sep. 30, 2012	9-May-13	Oct. 31, 2013
	Mar. 28, 2013	Mar. 28, 2012	Mar. 29, 2007	31-May-13	Sep. 30, 2013	Sep. 30, 2012	9-May-13	Subsequent Event [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'	'
Sales Agreement, Aggregate Offering Price, Common Stock	'	'	'	'	$44,400,000	'	'	'
Sales Agreement, Commission Percentage	'	'	'	'	2.00%	'	'	'
Sales Agreement, Termination Period	'	'	'	'	'10 days	'	'	'
Sales Agreement, Number of Shares Sold During Period	'	'	'	'	'	'	'	373,700
Sales Agreement, Average Share Price	'	'	'	'	'	'	'	$13.29
Sales Agreement, Net Proceeds	'	'	'	'	'	'	'	4,900,000
Stock Issued During Period, Shares, New Issues	'	'	'	3,903,004	'	'	'	'
Share Price	'	'	'	'	'	'	$4.14	'
Payments of Stock Issuance Costs	'	'	'	39,000	'	'	'	'
Proceeds from issuance of common stock	'	'	'	'	16,120,000	32,306,000	'	'
Period for issuance	'	'	'5 years	'	'	'	'	'
Shares of common stock to purchase by warrant	'	'	197,478	'	'	'	'	'
Exercise price of warrants	'	'	12.25	'	'	'	'	'
Extension period	'	'1 year	'	'	'	'	'	'
Warrant expiration date	29-Mar-14	29-Mar-13	'	'	'	'	'	'
Change in fair value of warrants	'	'	'	'	$41,000	$511,000	'	'

StockBased_Compensation_Narrat

Stock-Based Compensation - Narrative (Detail) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended	1 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Jan. 31, 2013	Sep. 30, 2013
					Equity Incentive Plan 2008	Equity Incentive Plan 2008	Equity Incentive Plan 2008	Equity Incentive Plan 2008
							Stock Option	Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Annual increase provision, allowable percentage	'	'	'	'	'	5.00%	'	'
Annual increase provision, maximum allowable shares	'	'	'	'	'	1,785,714	'	'
Increase in authorized shares	'	'	'	'	'	'	1,294,874	'
Stock options, number of shares reserved for issuance	'	'	'	'	7,520,691	7,520,691	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	'	611,359	611,359	'	'
Stock options, maximum term	'5 years 10 months	'6 years	'5 years 10 months	'5 years 8 months	'	'	'	'10 years
Stock options, average vesting period	'	'	'	'	'4 years	'	'	'
Unvested options outstanding	3,036,009	'	3,036,009	'	'	'	'	'
Unvested options outstanding, vesting period	'	'	'2 years 11 months	'	'	'	'	'
Unrecognized compensation expense	$16	'	$16	'	'	'	'	'

StockBased_Compensation_Fair_V

Stock-Based Compensation - Fair Value of Employee Option Grant Estimated on Date of Grant (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Estimated weighted-average fair value	$6.77	$6.63	$6.73	$3.32
Weighted-average assumptions	'	'	'	'
Expected volatility	88.00%	84.00%	87.00%	89.00%
Expected term, in years	'5 years 10 months	'6 years	'5 years 10 months	'5 years 8 months
Risk-free interest rate	1.66%	0.83%	1.65%	1.05%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

StockBased_Compensation_StockB

Stock-Based Compensation - Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total	$2,211	$576	$4,364	$2,276
Research and Development	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	1,371	282	2,518	1,135
Selling, General and Administrative Expenses	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$840	$294	$1,846	$1,141

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail) (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013
Options Outstanding	'
Beginning balance	5,390,582
Granted	1,734,301
Exercised	-49,343
Forfeited	-166,208
Ending balance	6,909,332
Vested and expected to vest	6,605,953
Exercisable	3,873,323
Weighted-Average Exercise Price per Share	'
Beginning balance	$5.18
Granted	$9.31
Exercised	$1.29
Forfeited	$7.42
Ending balance	$6.19
Vested and expected to vest	$6.08
Exercisable	$4.26
Weighted- Average Remaining Contractual Life	'
Balance	'7 years 4 months 2 days
Vested and expected to vest	'7 years 3 months
Exercisable	'5 years 9 months 25 days
Aggregate Intrinsic Value	'
Balance	$25,351
Vested and expected to vest	24,973
Exercisable	$21,525